drugset / Trial / NCT01913002
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
RandomizedCrossoverQuadruple-blindTreatment
Summary
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
Timeline
- Start
- 2013-07
- Primary completion
- 2013-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | Sotagliflozin | Small molecule | 800 mg | — |
| Subject | Sotagliflozin | Small molecule | 2000 mg | — |
Indications
No indication recorded.